Axon Enterprise, Inc $AXON Shares Purchased by Bessemer Group Inc.

Bessemer Group Inc. raised its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 3.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 231,839 shares of the biotechnology company’s stock after purchasing an additional 6,742 shares during the period. Bessemer Group Inc.’s holdings in Axon Enterprise were worth $98,460,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Baillie Gifford & Co. boosted its holdings in shares of Axon Enterprise by 1,198.7% in the 4th quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock valued at $932,869,000 after buying an additional 1,516,099 shares during the period. Edgewood Management LLC acquired a new position in Axon Enterprise in the fourth quarter valued at approximately $846,516,000. Wellington Management Group LLP grew its holdings in shares of Axon Enterprise by 326.9% during the fourth quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock valued at $874,463,000 after purchasing an additional 1,179,038 shares during the last quarter. Norges Bank acquired a new stake in shares of Axon Enterprise during the 4th quarter worth approximately $515,764,000. Finally, Sands Capital Management LLC boosted its position in Axon Enterprise by 11.6% during the 4th quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock valued at $914,047,000 after purchasing an additional 167,095 shares during the period. 79.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, CRO Cameron Brooks sold 1,242 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $500.00, for a total transaction of $621,000.00. Following the transaction, the executive owned 49,710 shares of the company’s stock, valued at approximately $24,855,000. This trade represents a 2.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick W. Smith sold 10,000 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $643.79, for a total transaction of $6,437,900.00. Following the sale, the chief executive officer owned 3,040,997 shares in the company, valued at $1,957,763,458.63. This trade represents a 0.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 58,989 shares of company stock valued at $30,527,983. 4.20% of the stock is currently owned by insiders.

Axon Enterprise Stock Down 5.8%

AXON opened at $510.28 on Friday. The stock’s 50 day moving average price is $471.67 and its 200 day moving average price is $481.88. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.27 and a quick ratio of 1.93. The stock has a market cap of $41.13 billion, a P/E ratio of 204.93, a P/E/G ratio of 11.05 and a beta of 1.38. Axon Enterprise, Inc has a 12 month low of $339.01 and a 12 month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The company had revenue of $807.35 million during the quarter, compared to analyst estimates of $778.90 million. During the same quarter in the previous year, the firm posted $1.47 EPS. The firm’s quarterly revenue was up 33.7% on a year-over-year basis. As a group, research analysts predict that Axon Enterprise, Inc will post 1.63 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Needham & Company LLC upped their price objective on Axon Enterprise from $600.00 to $750.00 and gave the stock a “buy” rating in a research note on Monday, July 6th. JPMorgan Chase & Co. boosted their price target on shares of Axon Enterprise from $750.00 to $755.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. UBS Group lowered their price target on shares of Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating for the company in a research report on Thursday, May 7th. Piper Sandler increased their price objective on shares of Axon Enterprise from $674.00 to $724.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Finally, Morgan Stanley set a $600.00 price objective on shares of Axon Enterprise in a research report on Thursday, May 7th. Fifteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Axon Enterprise currently has a consensus rating of “Moderate Buy” and a consensus target price of $725.25.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.